BioAge Labs, Inc Asset Resilience Ratio
BioAge Labs, Inc asset resilience ratio. BioAge Labs, Inc (BIOA) has an Asset Resilience Ratio of 61.67% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BIOA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BioAge Labs, Inc (2024–2025)
Asset resilience ratio of BioAge Labs, Inc from 2024 to 2025. This chart shows how BioAge Labs, Inc's Asset Resilience Ratio has changed over time. Read total liabilities of BioAge Labs, Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down BioAge Labs, Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BioAge Labs, Inc (BIOA) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $244.78 Million | 61.67% |
| Total Liquid Assets | $244.78 Million | 61.67% |
Asset Resilience Insights
- Very High Liquidity: BioAge Labs, Inc maintains exceptional liquid asset reserves at 61.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BioAge Labs, Inc Industry Peers by Asset Resilience Ratio
Compare BioAge Labs, Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
BioAge Labs, Inc Asset Resilience Ratio by Year (2024–2025)
BioAge Labs, Inc asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for BioAge Labs, Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 31.27% | $92.21 Million | $294.89 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $358.23 Million | -- |
About BioAge Labs, Inc
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhib… Read more